Related Experiment Video
Updated: May 16, 2026

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells
Julie Girouard1, Marie-Judith Lafleur, Sophie Parent
1Canada Research Chair in Molecular Gyneco-Oncology, Research Group in Molecular Oncology and Endocrinology, Department of Medical Biology, Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada G9A 5H7.
Objective:
In tumors, upstream regulation of Akt is affected by oncogenic events which lead to its constitutive activation and promote cell survival. Since studies have demonstrated that the three Akt isoforms exhibit different physiological functions, Akt isoforms may contribute differently in chemoresistance. The objective of the study was to determine the role of each Akt isoforms in chemoresistance.
Methods:
We stably transfected the chemoresistant KLE endometrial carcinoma cells with specific shRNAs for Akt1, Akt2 or Akt3. Alternatively, we stably transfected the chemosensitive Hec-1-A endometrial carcinoma cells, in which no Akt activity is detected, with constitutively active Akt expression vectors for each isoform.
Results:
We demonstrated that Akt1 and Akt2 downregulation by RNAi highly sensitizes KLE cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, -6, -9 and PARP; downregulation of all Akt isoforms leads to increased sensitivity to doxorubicin while only Akt1-2 downregulation increases taxol sensitivity. Proliferation of Akt1, and mostly Akt2 deficient cells was affected by cisplatin treatment. Constitutive Akt1 or Akt2 expression led to an increased resistance to apoptosis. Akt isoforms have been shown to influence migration in other cancer cells. We showed that Akt2 blocks cell motility, while Akt1-3 had less effect on our endometrial cancer cell models.
Conclusion:
Our findings highlight the contribution of Akt1 and Akt2 in the molecular mechanisms that govern chemoresistance of endometrial carcinomas. Furthermore, Akt isoform-specific transfectants will provide a strong model to determine the involvement of each Akt isoform in tumor progression and metastasis.
Insights
Akt1 and Akt2 play key roles in endometrial carcinoma chemoresistance. Downregulating these Akt isoforms sensitizes cancer cells to chemotherapy drugs like cisplatin, doxorubicin, and taxol.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Oncogenic events activate Akt signaling, promoting tumor cell survival and potentially contributing to chemoresistance.
- The three Akt isoforms (Akt1, Akt2, Akt3) have distinct physiological functions, suggesting differential roles in treatment resistance.
Purpose of the Study:
- To investigate the specific contribution of each Akt isoform (Akt1, Akt2, Akt3) to chemoresistance in endometrial carcinoma.
Main Methods:
- Stable transfection of chemoresistant KLE cells with Akt isoform-specific shRNAs.
- Stable transfection of chemosensitive Hec-1-A cells with constitutively active Akt isoform expression vectors.
Main Results:
- Akt1 and Akt2 downregulation sensitized KLE cells to cisplatin by activating apoptosis.
- Downregulation of all Akt isoforms increased doxorubicin sensitivity; Akt1/Akt2 downregulation enhanced taxol sensitivity.
- Akt1 and Akt2 expression conferred resistance to apoptosis; Akt2 influenced cell motility.
Conclusions:
- Akt1 and Akt2 are crucial in endometrial carcinoma chemoresistance mechanisms.
- Isoform-specific Akt manipulation models can elucidate roles in tumor progression and metastasis.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
